CardioMech taps medtech veteran Nehm for CEO Swedish mitral valve repair company CardioMech said today that it named medical device industry veteran Richard Nehm as president & CEO effective immediately. Nehm’s resume includes stints at Boston Scientific (NYSE:BSX), Abbott (NYSE:ABT) acquisition Tendyne and ATS Medical (acquired by Medtronic (NYSE:MDT)). CardioMech also named Spinal Stabilization Technologies president […]
Restoration Robotics (NASDAQ:HAIR) has launched a robotic intelligent system that offers precise, minimally invasive, repeatable hair harvesting and implantation uses in one platform. The Artas iX robotic hair restoration system has a 3-camera stereoscopic vision system with 44-micron resolution and a 7-axis robot. It has a compact, motorized, battery-powered, portable and adjustable procedure chair for increased patient comfort and […]
Robotic hair restoration company Restoration Robotics has raised $25 million in an initial public offering and seen its shares rise nearly 40% after its debut, according to a Silicone Valley Business Journal report. The 91-person company, co-founded by surgical robotics pioneer Fred Moll, sold 3.6 million shares at $7 each, then proceeded to open at […]
Cook Medical touts FDA win for next-gen colonic stent
Cook Medical won FDA clearance for the latest of its Evolution line, the Colonic Controlled-Release stent.
AngioDynamics Inc. (NSDQ:ANGO) named a replacement for former CEO Jan Keltjens, who left suddenly in June, tapping Joseph DeVivo for the corner office.
The Latham, N.Y.-based oncology device company also revealed the resignation of senior vice president of business development Lynda Wallace, according to SEC filings.
MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–Restoration Robotics, Inc. a privately-held medical device company, today announced the promotion of one of its founders, Mohan Bodduluri to Chief Technology Officer.
“We are proud of ARTAS System where advanced technologies come together into an easy-to-use and safe solution that benefit both physicians and patients. I am excited about the extension of my role in driving the technology leadership for the company and in continuing to work closely with our customers”
Edwards Lifesciences Corp. (NYSE:EW) landed a new four-year $500 million credit facility after canceling a prior one a couple months early.
The old facility was a five-year deal, also for $500 million, that was scheduled to mature September 29, 2011.